<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998813</url>
  </required_header>
  <id_info>
    <org_study_id>CHD038-19</org_study_id>
    <nct_id>NCT03998813</nct_id>
  </id_info>
  <brief_title>Chronic Pain and Functional Prognosis After Total Knee Replacement: Continuous Locoregional Analgesia by Catheter to the Femoral Triangle Versus Tissue Infiltration as Part of an Improved Rehabilitation After Surgery Approach</brief_title>
  <acronym>TKAFTER</acronym>
  <official_title>Chronic Pain and Functional Prognosis After Total Knee Replacement: Continuous Locoregional Analgesia by Catheter to the Femoral Triangle Versus Tissue Infiltration as Part of an Improved Rehabilitation After Surgery Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of Chronic Post-Surgical Pain (CPSP) after knee replacement, defined as pain&#xD;
      greater than or equal to 4/10 on the visual analogue scale after the third postoperative&#xD;
      month, is recognised as high, with an average of 20% (extremes of 7 to 45%).&#xD;
&#xD;
      These CPSP, when present, cause poor long-term joint functional prognosis and impaired&#xD;
      quality of life for patients. Many predictive, pre-, per- and post-operative factors of these&#xD;
      CPSP have been identified in recent years. The most common postoperative risk factor found in&#xD;
      the literature is the intensity of early pain.&#xD;
&#xD;
      The treatment protocols for this early post-surgical pain are currently and mainly multimodal&#xD;
      in nature, combining systemic analgesics (paracetamol, NSAIDs, morphine, gabapentins) and&#xD;
      local anaesthetics, administered either in the form of peripheral nerve blocks (continuous or&#xD;
      single injection) or in the form of tissue infiltration (TI) performed by the surgeon during&#xD;
      the operation.&#xD;
&#xD;
      Very few of these techniques have been evaluated for their ability to reduce the incidence of&#xD;
      CPSP. Drugs with antihyperalgesic properties such as ketamine or nefopam have been shown to&#xD;
      be of no interest, except to reduce the proportion of pain of a neuropathic nature. Only the&#xD;
      continuous femoral block has shown, to date, an interest in IT to reduce the incidence of&#xD;
      these CPSP.&#xD;
&#xD;
      The main objective of this study is to show that a multimodal analgesia protocol based on&#xD;
      continuous locoregional analgesia by femoral triangle catheterization could reduce the&#xD;
      incidence of chronic post surgical pain compared to a protocol based on tissue infiltration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A walking pain assessment scale greater than or equal to 4</measure>
    <time_frame>Three months from the intervention</time_frame>
    <description>Self-assessment scale to quantify the patient's pain on a virtual scale from 0 (no pain) to 10 (maximum pain imaginable)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Knee Pain Chronic</condition>
  <arm_group>
    <arm_group_label>Locoregional analgesia by femoral triangle catheterization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tissue infiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Locoregional analgesia by femoral triangle catheterization</description>
    <arm_group_label>Locoregional analgesia by femoral triangle catheterization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Tissue infiltration</description>
    <arm_group_label>Tissue infiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient;&#xD;
&#xD;
          -  Placement of unilateral tricompartmental knee prosthesis for gonarthrosis;&#xD;
&#xD;
          -  ASA score between I and III ;&#xD;
&#xD;
          -  Nonseptic scheduled surgery;&#xD;
&#xD;
          -  Knee replacement scheduled on one of the first 3 days of the week (Monday to Wednesday&#xD;
             included) in order to benefit from a homogeneous postoperative physical therapy;&#xD;
&#xD;
          -  Able to understand the protocol;&#xD;
&#xD;
          -  Having agreed to participate in the study and having given express oral consent;&#xD;
&#xD;
          -  Affiliated with a social security system;&#xD;
&#xD;
          -  Possibility of being followed as part of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 85 years old;&#xD;
&#xD;
          -  BMI &gt; 35 ;&#xD;
&#xD;
          -  Revision of knee replacement;&#xD;
&#xD;
          -  Symptomatic contralateral osteoarthritis;&#xD;
&#xD;
          -  Anterior of surgery on the operated knee (excluding arthroscopy and meniscectomy);&#xD;
&#xD;
          -  Vascular surgery on the femoral vessels on the operated side;&#xD;
&#xD;
          -  Concept of diffuse polyalgia syndrome (fibromyalgia);&#xD;
&#xD;
          -  Documented neuropathy of the lower limb;&#xD;
&#xD;
          -  Localized infection at the catheter puncture site (femoral triangle);&#xD;
&#xD;
          -  Known allergy to Ropivacaine;&#xD;
&#xD;
          -  Renal insufficiency (Clearance - CKD-EPI formula - creatinine &lt;30 ml/min) and/or&#xD;
             severe hepatic insufficiency (prothrombin blood level &lt;50%) ;&#xD;
&#xD;
          -  Inflammatory rheumatic disease (rheumatoid arthritis, ankylosing spondylitis...) ;&#xD;
&#xD;
          -  Patient on immunosuppressive treatment or corticosteroid therapy;&#xD;
&#xD;
          -  Tier III morphine intake for more than a month before surgery;&#xD;
&#xD;
          -  Known intolerance to morphine;&#xD;
&#xD;
          -  Allergy or contraindications to standard treatments administered per and&#xD;
             postoperatively (paracetamol, NSAIDs);&#xD;
&#xD;
          -  Patient undergoing knee surgery in the year prior to inclusion and participating in&#xD;
             the study;&#xD;
&#xD;
          -  Patients who do not cooperate or do not understand French, difficulties in&#xD;
             understanding and evaluating the pain score, preoperative cognitive dysfunction making&#xD;
             the interview unreliable;&#xD;
&#xD;
          -  Patient under guardianship, curators, deprivation of liberty;&#xD;
&#xD;
          -  Patient already engaged in another interventional clinical study (category 1);&#xD;
&#xD;
          -  Pregnant or breastfeeding women, or women in a position to procreate who refuse an&#xD;
             effective means of contraception;&#xD;
&#xD;
          -  Refusal to participate;&#xD;
&#xD;
          -  Inability to understand the protocol and its requirements, and/or to give express oral&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme GUILLEY</last_name>
    <role>Study Director</role>
    <affiliation>CHD Vendée</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chloé MOREAU</last_name>
    <phone>0251446572</phone>
    <email>chloemoreau@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jérôme GUILLEY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sabeha KACIMI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Sévigné</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christophe AVELINE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

